Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Stryker Corporation — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.83, while Stryker Corporation trades at $347.43 (market cap $132.64B). The key difference: Stryker Corporation pays a 1.02% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and Stryker Corporation is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMB | SYK | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $97.74 | $394.34 |
52-Week Low | $92.95 | $282.58 |
Market Cap | — | $132.64B |
Enterprise Value | — | $144.11B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB, the iShares J.P. Morgan USD Emerging Markets Bond ETF, trades at $95.24, up 0.31% over 24 hours. Technical indicators are mixed, with a neutral overall signal and bearish moving averages. Recent dividend distributions provide income, but key financial ratios are unavailable. News sentiment highlights yield-driven returns amid emerging market sovereign risks.
Outlook hinges on income from its 5.1% yield, with limited price upside expected. Risks include emerging market defaults and Federal Reserve policy shifts. Analysts rate it a hold, emphasizing diversification benefits but cautioning on macro triggers.
Stryker (SYK) trades at $339.03, up 0.47% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $3.69 versus $3.49 expected, and demonstrated robust 9% organic sales growth. Analyst consensus is strongly positive with a $379.44 price target and 74% buy ratings. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS robotic technology.
The outlook remains favorable given earnings momentum and product innovation, though risks include competitive pressures and potential cyber disruptions. Valuation multiples such as a P/E of 35.84 suggest premium pricing, requiring sustained growth to justify. Institutional ownership trends show mixed activity, with some funds increasing stakes recently.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
